Table 1.
Baseline characteristics after propensity score matching.
| Characteristics | Sofosbuvir-Based (n = 835) |
Sofosbuvir-Free (n = 835) |
Standardized Mean Difference * |
|---|---|---|---|
| Age | 67 (56–75) | 67 (57–74) | 0.04 |
| Male | 365 (43.7) | 360 (43.1) | 0.02 |
| Body Mass Index (kg/m2) | 22.9 (20.6–25.3) | 22.7 (20.6–25.0) | 0.11 |
| Cirrhosis | 225 (26.9) | 218 (26.1) | 0.02 |
| Diabetes | 151 (18.2) | 129 (15.4) | 0.10 |
| Treatment-Naïve | 613 (73.4) | 621 (74.4) | 0.03 |
| Total Bilirubin (mg/dL) | 0.7 (0.6–0.9) | 0.7 (0.5–0.9) | 0.09 |
| Albumin (g/dL) | 4.1 (3.8–4.3) | 4.1 (3.8–4.3) | 0.03 |
| AST (U/L) | 42 (29–62) | 42 (29–63) | 0.08 |
| ALT (U/L) | 40 (26–63) | 39 (25–66) | 0.07 |
| γGTP (U/L) | 32 (20–58) | 32 (20–57) | 0.02 |
| eGFR (mL/min/1.73 m2) | 72 (62–84) | 74 (62–86) | 0.01 |
| Platelet count (103/ μ L) | 159 (117–205) | 161 (118–205) | 0.05 |
| α-fetoprotein (ng/mL) | 4.5 (2.9–8.0) | 4.4 (2.8–8.3) | 0.03 |
| HCV RNA (logIU/mL) | 6.1 (5.5–6.5) | 6.1 (5.6–6.5) | 0.14 |
| HCV Genotype | |||
| Genotype 1 | 497 (59.5) | 705 (84.4) | |
| Genotype 2 | 338 (40.5) | 130 (15.6) | 0.82 |
| Other Genotypes | 0 | 0 | |
| DAA regimen | |||
| LDV/SOF | 500 (59.9) | - | |
| SOF + RBV | 335 (40.1) | - | |
| ASV + DCV | - | 314 (37.6) | |
| EBR + GZR | - | 227 (27.2) | |
| GLE/PIB | - | 216 (25.9) | |
| 2D | - | 78 (9.3) |
Data are expressed as median (first-third quartiles) or number (%). AST, aspartate aminotransferase; ALT, alanine aminotransferase; γGTP, gamma-glutamyl transpeptidase; eGFR, estimated glomerular filtration rate; HCV, hepatitis C virus; DAA, direct-acting antiviral; LDV, ledipasvir; SOF, sofosbuvir; RBV, ribavirin; ASV, asunaprevir; DCV, daclatasvir; EBR, elbasvir; GZR, grazoprevir; GLE, glecaprevir; PIB, pibrentasvir; 2D, ombitasvir/paritaprevir/ritonavir. * Values < 0.1 indicate adequate balance between the SOF-based and SOF-free groups.